Comparison of Quality of Life in Patients with β-Thalassemia Intermedia and β-Thalassemia Major in Southern Iran

References

• Thavorncharoensap M, Torcharus K, Nuchprayoon I, et al. Factors affecting health-related quality of life in Thai children with thalassemia. BMC Blood Disord. 2010;10:1.
   PubMedGoogle Scholar
• Abdul-Zahra HA, Hassan MK, Ahmed BA. Health-related quality of life in children and adolescents with β-thalassemia major on different iron chelators in Basra, Iraq. J Pediatr Hematol Oncol. 2016;38(7):503–511.
   PubMed Web of Science ®Google Scholar
• Safizadeh H, Farahmandinia Z. Quality of life in patients with thalassemia major and intermedia in Kerman-Iran (IR). Mediterr J Hematol Infect Dis. 2012;4(1):e2012058.
   PubMedGoogle Scholar
• Baghianimoghadam MH, Sharifirad G, Rahaei Z, et al. Health related quality of life in children with thalassaemia assessed on the basis of SF-20 questionnaire in Yazd, Iran: a case-control study. Cent Eur J Public Health. 2011;19(3):165–169.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin Ther. 2007;29(5):909–917.
   PubMed Web of Science ®Google Scholar
• Payne KA, Rofail D, Baladi J-F, et al. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther. 2008;25(8):725–742.
   PubMed Web of Science ®Google Scholar
• Abetz L, Baladi J-F, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes. 2006;4:73.
   PubMed Web of Science ®Google Scholar
• Dhirar N, Khandekar J, Bachani D, Mahto D. Thalassemia major: how do we improve quality of life? SpringerPlus. 2016;5(1):1895. eCollection 2016.
   PubMed Web of Science ®Google Scholar
• Origa R. β-Thalassemia. Genet Med. 2017;19(6)609–619.
   PubMed Web of Science ®Google Scholar
• Caocci G, Efficace F, Ciotti F, et al. Health related quality of life in Middle Eastern children with β-thalassemia. BMC Blood Disord. 2012;12:6.
   PubMedGoogle Scholar
• Telfer P, Constantinidou G, Andreou P, et al. Quality of life in thalassemia. Ann NY Acad Sci. 2005;1054:273–282.
   PubMed Web of Science ®Google Scholar
• Lal A, Vichinsky E. The role of fetal hemoglobin-enhancing agents in thalassemia. Semin Hematol. 2004;41(4Suppl6):17–22.
   Web of Science ®Google Scholar
• Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380–385.
   PubMed Web of Science ®Google Scholar
• Piga A, Perrotta S, Gamberini MR, et al. Luspatercept (ACE-536) reduces disease burden, including anemia, iron overload, and leg ulcers, in adults with β-thalassemia: results from a Phase 2 study. Blood. 2015;126(23):752.
   Web of Science ®Google Scholar
• Carrancio S, Markovics J, Wong P, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol. 2014;165(6):870–882.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886–1892.
   PubMed Web of Science ®Google Scholar
• Pakbaz Z, Treadwell M, Yamashita R, et al. Quality of life in patients with thalassemia intermedia compared to thalassemia major. Ann NY Acad Sci. 2005;1054:457–461.
   PubMed Web of Science ®Google Scholar
• Megari K. Quality of life in chronic disease patients. Health Psychol Res. 2013;1(3)e27.
   PubMedGoogle Scholar
• Caocci G, Efficace F, Ciotti F, et al. Prospective assessment of health-related quality of life in pediatric patients with β-thalassemia following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(6):861–866.
   PubMed Web of Science ®Google Scholar
• Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res. 2005;14(3):875–882.
   PubMed Web of Science ®Google Scholar
• Jafari H, Lahsaeizadeh S, Jafari P, Karimi M. Quality of life in thalassemia major: reliability and validity of the Persian version of the SF-36 questionnaire. J Postgrad Med. 2008;54(4):273–275.
   PubMed Web of Science ®Google Scholar
• Haghpanah S, Nasirabadi S, Ghaffarpasand F, et al. Quality of life among Iranian patients with β-thalassemia major using the SF-36 questionnaire. Sao Paulo Med J. 2013;131(3):166–172.
   PubMed Web of Science ®Google Scholar
• La Nasa G, Caocci G, Efficace F, et al. Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. Blood. 2013;122(13):2262–2270.
   PubMed Web of Science ®Google Scholar
• Sloan J, Symonds T, Vargas-Chanes D, Fridley B. Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inf J. 2003;37(1):23–31.
   Google Scholar
• Cheuk D, Mok A, Lee A, et al. Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT. Bone Marrow Transplant. 2008;42(5):319–327.
   PubMed Web of Science ®Google Scholar
• Clarke S, Skinner R, Guest J, et al. Health related quality of life and financial impact of caring for a child with thalassaemia major in the UK. Child Care Health Dev. 2010;36(1):118–122.
   PubMed Web of Science ®Google Scholar
• Gollo G, Savioli G, Balocco M, et al. Changes in the quality of life of people with thalassemia major between 2001 and 2009. Patient Prefer Adherence. 2013;7(23):231–236.
   PubMed Web of Science ®Google Scholar
• Majdi M, Marzabadi A. Quality of life in Iranian β-thalassemia major patients of southern coastwise of the Caspian Sea. Int J Behavioral Sci. 2009;2(4):325–332.
   Google Scholar
• Soni S, Thawani R, Idhate T, et al. Health related quality of life in patients with transfusion-dependent thalassemia. Indian Pediatr. 2016;53(8):741–742.
   PubMed Web of Science ®Google Scholar
• Azarkeivan A, Hajibeigi B, Lankarani MM, et al. Associates of poor physical and mental health-related quality of life in β thalassemia-major/intermedia. J Res Med Sci. 2009;14(6):349–355.
   PubMed Web of Science ®Google Scholar
• Surapolchai P, Satayasai W, Sinlapamongkolkul P, Udomsubpayakul U. Biopsychosocial predictors of health-related quality of life in children with thalassemia in Thammasat University Hospital. J Med Assoc Thai. 2010;93(Suppl7):S65–S75.
   Google Scholar
• Sobota A, Yamashita R, Xu Y, et al. Quality of life in thalassemia: a comparison of SF 36 results from the thalassemia longitudinal cohort to reported literature and the US norms. Am J Hematol. 2011;86(1):92–95.
   PubMed Web of Science ®Google Scholar
• Porter J, Bowden DK, Economou M, et al. Health-related quality of life, treatment satisfaction, adherence and persistence in β-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the EPIC clinical trial. Anemia. 2012;2012:297641.
   PubMedGoogle Scholar